Retrospective Study to Develop a Training Set for a Cross Validated Chemoresponse Marker Algorithm in Cases With Ovarian, Peritoneal or Fallopian Tube Cancer
This is a multicenter, retrospective chart review study of de-identified drug response
marker results and a limited data set of clinical outcome data. Data from approximately 512
cases will be collected from approximately 30 sites and correlated to the secondary
endpoints identified in order to produce a training set that will incorporate additional
improvements to the existing ChemoFx scoring system. The outcome of progression free
survival will be defined as the period of time between the first dose of chemotherapy
following the report of the marker result until clinical progression or death. Objective
response will be measured from the first dose of chemotherapy following the report of the
marker result until progression or change in therapy.
Observational
Observational Model: Case-Only, Time Perspective: Retrospective
Holly Gallion, MD
Study Director
Vice President, Clinical Affairs
United States: Institutional Review Board
PT-103
NCT01048814
August 2009
June 2011
Name | Location |
---|---|
Precision Therapeutics, Inc. | Pittsburgh, Pennsylvania 15203 |